Pharmaceutical CDMO/CMO Specialist with Expertise in Drug Product Development and CMC


CMO Selection Process and Contract Negotiation

Supply Chain Creation

Alliance Management

Combination Drug Product Development



Risk Management


xCell Strategic Consulting – Principal

Dionis Pharma, LLC – Owner

Patheon – Business Development Manager

MicroDose Therapeutx – Associate Director, Solid Oral Dosage Forms

Shionogi Qualicaps, Inc. – Strategic Business Manager

MDS Pharma Services – Associate Director

Ivax – Scientist

Wyeth – Chemist


NJ Pharmaceutical Association for Science and Technology

American Association of Pharmaceutical Scientists

NJ Technical Council

Licensing Executives Society


MS, Industrial Pharmacy, Long Island University

BA, Chemistry, Amherst College

CE, Clinical Development, Mercer County Community College




Ray Sison, Principal

Ray has over 20 years of achievements managing pharmaceutical drug product development and commercialization efforts.  He has extensive experience in program management, outsourced manufacturing, CTM logistics, equipment design/commissioning and facility improvement.  His hands-on problem solving approach and strong technical expertise have earned him a reputation as a matrix management leader for fast-paced dynamic organizations.  He has real-time experience in the lab and cGMP production floor.


  • Established a supply chain for a clinical stage development company to support the commercialization of a 505(b)2 NDA drug/device combination product (dry powder inhaler) that is currently pending FDA approval.  The new supply chain operation enhanced the successful out- licensing of the product.
  • Championed development programs for unique dosage delivery systems for virtual and specialty pharmaceutical companies resulting in expanded IP portfolios and more effective commercialized platform technologies including solid oral, liquid, pulmonary and nasal delivery systems.
  • Led sales and marketing efforts for mid-tier and global CDMO/CMOs resulting in strategic partnerships with specialty pharmaceutical companies that drove revenue of $6M to $12M annually.